Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-In-Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CND319 in Healthy Participants and Patients With Rheumatic Diseases

NCT07712939 is registered in ClinicalTrials.gov with Candid Therapeutics as lead sponsor.

NCT NCT07712939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07712939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-In-Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CND319 in Healthy Participants and Patients With Rheumatic Diseases
Lead sponsor
Candid Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
July 20, 2026
Completion date
March 31, 2028
Enrollment
105 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants study, rheumatoid arthritis, sjogren's syndrome